What Is Acquired Hypothalamic Obesity?
Acquired hypothalamic obesity can occur when the hypothalamus is damaged or impaired. The region of the brain plays an important role in regulating hunger, energy balance and other processes linked to body weight.
The condition can develop following events or treatments that affect the hypothalamus. People living with the condition can experience severe and persistent weight gain alongside changes in hunger and energy expenditure.
Unlike common forms of obesity, acquired hypothalamic obesity is linked to an underlying disruption involving the brain's regulation of energy balance. This makes treatment particularly challenging.
How Does IMCIVREE Work?
IMCIVREE contains setmelanotide, a melanocortin-4 receptor, or MC4R, agonist. The treatment is designed to activate the MC4R pathway, which plays an important role in regulating hunger and energy balance.
Rhythm Pharmaceuticals has been developing setmelanotide as a precision medicine for rare forms of obesity involving disruptions in the MC4R pathway.
The treatment is administered by subcutaneous injection. Health Canada's existing product information lists IMCIVREE as a prescription pharmaceutical containing setmelanotide.
What Did the Clinical Trial Show?
The Canadian announcement follows results from the Phase 3 TRANSCEND trial evaluating setmelanotide in patients with acquired hypothalamic obesity.
The expanded dataset included 142 patients. According to Rhythm Pharmaceuticals, patients receiving setmelanotide achieved an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks.
The mean BMI change was a 16.4% reduction from baseline among patients receiving setmelanotide, compared with a 2.4% increase among patients receiving placebo.
The study also assessed hunger among patients aged 12 and older. The company reported a greater reduction in weekly average most-hunger scores among patients receiving setmelanotide compared with those receiving placebo.
These results formed part of the evidence supporting the company's regulatory submissions for acquired hypothalamic obesity.
What the Canadian Approval Means
The approval gives eligible patients with acquired hypothalamic obesity another treatment option specifically designed to target the biological pathway involved in hunger and energy regulation.
The development is also significant because acquired hypothalamic obesity is a distinct condition that can emerge following hypothalamic injury or impairment. Treatment therefore requires an approach that addresses the underlying pathway rather than relying only on conventional weight-management strategies.
Rhythm Pharmaceuticals said it will continue working to support access to IMCIVREE for eligible patients across Canada.
IMCIVREE Already Had an Earlier Canadian Approval
IMCIVREE is not a completely new medicine in Canada.
Health Canada's public drug records show that setmelanotide received its original Notice of Compliance in May 2023. The existing product is marketed in Canada as IMCIVREE and contains setmelanotide acetate.
The September 22 announcement concerns the use of IMCIVREE for acquired hypothalamic obesity, expanding its role beyond its earlier approved uses.
Health Canada's public submissions database also lists a supplemental setmelanotide submission from Rhythm Pharmaceuticals under review. The public database may therefore take additional time to reflect the latest regulatory development announced by the company.
A New Chapter for Rare Obesity Treatment
The latest decision adds to the growing development of targeted medicines for rare forms of obesity. Rather than treating obesity as a single condition, researchers are increasingly focusing on the biological mechanisms that can drive severe weight gain in specific patient groups.
For people with acquired hypothalamic obesity, the Canadian approval could provide access to a therapy specifically designed around the MC4R pathway.
The next stage will focus on availability, access and real-world use among eligible patients across Canada.